Lonza Advances Manufacturing Strategy - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Lonza Advances Manufacturing Strategy


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Basel, Switzerland (Dec. 5)—Lonza Group Ltd. (www.lonza.com) and Singapore’s Bio*One Capital (www.bio1capital.com) have formed a joint venture, Lonza Biologics Tuas, to build a large-scale mammalian cell-culture facility in Singapore for as much as $350 million. Bio*One Capital is the investment arm of the Singapore Economic Development Board (www.edb.gov.sg).

The new facility under Lonza Biologics Tuas will have up to four mammalian bioreactor trains, each with a flexible capacity of 1,000–20,000 liters and inclusive of purification units. The plant will be constructed over two phases. Construction of the shell will begin in February 2007. Final build-out of the facility is scheduled for completion and operation no later than 2011. Lonza Biologics Tuas expects to hire 350 people to staff the operation. 

The facility will be Lonza’s second large-scale mammalian manufacturing plant in Singapore, and its third one overall. Lonza and Bio*One Capital entered into an initial joint venture, Lonza Biologics Singapore Pte Ltd, in February 2006 to build an 80,000-liter large-scale mammalian biopharmaceutical production facility. Lonza took 100% ownership of this facility upon the signing of the Lonza Biologics Tuas joint venture. Genentech, Inc. (South San Francisco, CA, www.gene.com) has the exclusive option to acquire the Lonza-owned facility between 2007 and 2012.

Lonza announced last month its plan to give Genentech the option to purchase the Singapore facility, see ePT story, “Genentech and Lonza Sign Pact for Manufacturing Facilities and Supply.” As part of the plan, Lonza also agreed to buy Genentech’s mid-scale mammalian biopharmaceutical production plant in Porriño, Spain for $150 million. This week, Lonza and Genentech closed that deal. The new facility, which has 40,000 liters of biologics manufacturing capacity, is named Lonza Biologics Porriño S.L. Lonza will retain the facility’s 310 employees.

Lonza inks API pact with Solvay

In other news, Lonza formed a long-term strategic manufacturing alliance with Solvay Pharmaceuticals, Inc. (Marietta, GA, www.solvaypharmaceuticals-us.com) under which Lonza will produce a selection of Solvay’s large-volume active pharmaceutical ingredients (APIs). The agreement builds on an existing API commercial partnership between the companies.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here